SCHEMBL13610792

SCHEMBL13610792

CNC(=O)C1Cc2ccccc2N1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.65
MAPT P10636 1/20 0.65
SMYD3 Q9H7B4 1/20 0.45
MTNR1A P48039 3/20 0.41
MTNR1B P49286 1/20 0.41
EPHX2 P34913 1/20 0.40
BRD4 O60885 1/20 0.39
CREBBP Q92793 1/20 0.39
REN P00797 1/20 0.38
MASP2 O00187 1/20 0.38
F2 P00734 1/20 0.38
CTSD P07339 1/20 0.37
HTR1A P08908 2/20 0.36
HTR2A P28223 2/20 0.36
DRD3 P35462 2/20 0.36
GRM7 Q14831 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30146036 1.00 GAA (0.65) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL29082747 0.85 GAA (0.67) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL8567341 0.84 SMYD3 (0.63) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL8567344 0.84 SMYD3 (0.63) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL8567346 0.84 SMYD3 (0.63) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL7045251 0.83 GAA (0.59) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL25937486 0.81 SMYD3 (0.53) GAAMAPTSMYD3MTNR1AMASP2
SCHEMBL8284981 0.81 GAA (0.71) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL16523130 0.81 GAA (0.71) GAAMAPTSMYD3MTNR1AMTNR1B
SCHEMBL8294731 0.81 GAA (0.71) GAAMAPTSMYD3MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024097855-A2 IDENTIFICATION OF SMALL MOLECULES THAT RECRUIT AND ACTIVATE RNASE L UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-05-10 WO disclosed
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORP (CA) 2023-10-05 US disclosed
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-09-21 US disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed
CN-115551864-A Substituted tricyclic amides, analogs thereof, and methods of using the same 爱彼特生物制药公司 2022-12-30 CN disclosed
US-20090280106-A1 Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use BAYER PHARMACEUTICALS CORPORATION (US) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090280106-A1 Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use ADCYAP1R1, VIPR2, ADCY2 GAA 1992/4885MAPT 4286/4885SMYD3 4049/4885
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME HCCS, HAVCR2, HDGF GAA 2197/4885MAPT 3938/4885SMYD3 558/4885
US-20230312481-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF NSD3, PML, NSD1 GAA 2522/4885MAPT 484/4885SMYD3 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.